Zoetis (ZTS) is a Pharmaceuticals company. Zoetis develops and sells medicines, vaccines, and diagnostics for companion animals and livestock. Companion-animal products were about 70% of 2025 revenue. It was founded in 1952, is headquartered in Parsippany, New Jersey and employs about 14,500 people.

How does Zoetis make money?

As of 2026-Q2, Zoetis's revenue breaks down across Dogs and Cats (68%), Cattle (16%), Swine (5%), Poultry (5%). See the revenue-by-segment chart for the full mix.

How has Zoetis's revenue and profitability trended?

Track Zoetis's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.

Who are Zoetis's main competitors?

Sterling groups Zoetis in the Healthcare sector, alongside Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Viatris (VTRS).

If I'm investing in Zoetis, what similar companies should I consider?

If you are researching Zoetis, also look at Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Viatris (VTRS). You can compare all of them side by side or browse the full Healthcare sector on Sterling.